Duvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat

Imported from official source

There have been several reports internationally of deaths in patients with Duchenne muscular dystrophy (DMD) while being treated with Duvyzat® (givinostat). Following a review of these cases and associated evidence, the MHRA has proposed updates to the product information.

This version

Version
1 of 1
Recorded
November 05, 2026 13:02
Change
Initial
Content hash
8717004856b92248c3f056aa52409e71
All versions
Revision history

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.